-39.2%
NCLH vs MRNA
+511.3%
-550.5%
-45.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.1% | -2.2% | +2.1% | -0.1% |
| 7D | -6.5% | +5.5% | -12.0% | -6.6% |
| 30D | -23.3% | +158.7% | -182.0% | -27.3% |
| 3M | -18.6% | +182.1% | -200.7% | -25.8% |
| 6M | -26.2% | +151.8% | -178.1% | -31.6% |
| YTD | -30.2% | +393.6% | -423.8% | -44.8% |
| 1Y | -39.2% | +499.5% | -538.6% | -53.3% |
| All | -39.2% | +511.3% | -550.5% | -53.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling